Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07531719) titled 'A Study of Risdiplam in Participants With Type I and Type II Spinal Muscle Atrophy (SMA)' on April 8.

Study Type: Observational

Primary Sponsor: Hoffmann-La Roche

Condition: Spinal Muscle Atrophy

Recruitment Status: Not recruiting

Date of First Enrollment: April 15, 2026

Target Sample Size: 30

To know more, visit https://clinicaltrials.gov/study/NCT07531719

Disclaimer: Curated by HT Syndication....